26
Oct
2021
DNA Script Snags $165M to Build Up Benchtop DNA Synthesis Market, Technology
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
21
Oct
2021
Biogen’s Face-plant, an Interchangeable Humira, & Boosters OK’d
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
20
Oct
2021
ADCs: If at First You Don’t Succeed…
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
14
Oct
2021
Califf Back at FDA? Moderna’s Booster Slam Dunk, & the Vaccine Equity Debate
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
12
Oct
2021
5 Themes to Track at ASHG 2021
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
12
Oct
2021
Reimagining DNA Sequencing With Long Reads: Christian Henry on The Long Run
Today’s guest on The Long Run is Christian Henry. Christian is the CEO of Menlo Park, Calif.-based PacBio. It makes DNA sequencing instruments that are used by scientists around the world. The company has long toiled in the shadow of the market leader – some would say monopolist in DNA Sequencing – Illumina. PacBio was way overhyped in its early... Read More
7
Oct
2021
Collins Exits NIH; WHO Backs GSK Malaria Vaccine; RA, MPM, Atlas Reload
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
7
Oct
2021
Neumora Secures $500M, Amgen Deal, in Quest for Precision Neuroscience R&D
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
6
Oct
2021
RNA 2.0 Startups Take Aim at Improved Delivery, Target Specificity
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
5
Oct
2021
Exo Pockets $78M to Make Small Molecules Against Exosite Targets
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
4
Oct
2021
Pharma’s Digital Transformation: Enduring Challenges, Sustained Hopes, And A Progress Report From Lilly’s CEO
When it comes to emerging digital and data technologies, most pharma CEOs today are singing from the same hymnal. They all emphasize their commitment to digital transformation, and assert that the adoption of digital processes are key to their companies’ success, and vital for the industry’s future. A recent Lazard survey of healthcare leaders echoes this message. The investment bank... Read More
30
Sep
2021
Merck Buys Acceleron, Regeneron Antibody Saves Lives, & Moderna Invests in Cambridge
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
29
Sep
2021
Expansion Snags $80M to Make Small Molecules Against RNA Targets
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
27
Sep
2021
Sequencing Genomes of Indigenous Populations: Keolu Fox on The Long Run
Today’s guest on The Long Run is Keolu Fox. Keolu is an assistant professor at UCSD with a fascinating mix of interests. He’s a Native Hawaiian, and got his PhD in genome sciences from the University of Washington. He’s now taking that mix of life experience and scientific training, and putting it to work on projects that sequence the DNA... Read More
23
Sep
2021
J&J Bounces Back, Illumina-Grail Scrutiny, & AZ’s HER-2 ADC Triumph
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
20
Sep
2021
A Magical Time in the Presidential Range, Giving Back to Community
The Timmerman Traverse for Life Science Cares was everything I dreamed it would be. Here’s a quick recap: The team of 20 raised $706,000 to fight poverty 51 sponsors participated About 530 individuals contributed We lucked out with the weather For those unfamiliar, the Timmerman Traverse for Life Science Cares brought together a team of 20 biotech executives and investors... Read More
20
Sep
2021
What Should I Read? A Few Suggestions for Biotech Pros
Although we are all impossibly busy, most people I know in the biotech industry still make time to read books. Books may sometimes have a hard time competing with flashier forms of media in the online attention economy, but they aren’t going away anytime soon. This seems especially true now that so many titles are available in audiobook form, enabling... Read More
15
Sep
2021
Hero Narratives Inspire Entrepreneurs But Obscure Uncomfortable Trade-Offs
In today’s Wall Street Journal, I discuss Reid Hoffman’s Masters of Scale, a new book by the renowned Silicon Valley entrepreneur (PayPal, LinkedIn), investor (Facebook, Airbnb), and podcast host that proposes to distill the secrets of successful business and social entrepreneurs. The review speaks for itself, of course, but Hoffman’s account, and others like it (there are many – for... Read More
12
Sep
2021
Turning Around COVID Diagnostics. Mara Aspinall on The Long Run
Today’s guest on The Long Run is Mara Aspinall. Mara is a veteran diagnostics executive, investor, and educator. She’s a venture investor with Bluestone Venture Partners, the CEO of Health Catalysts (a consulting firm), and the co-founder and professor of the practice of biomedical diagnostics at Arizona State University. It’s the only program of its kind in the country, designed... Read More
9
Sep
2021
Versant, OrbiMed Invest $50M in Startup Inserting Genes in the Liver
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.